Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline
Shots:
- Novartis has agreed to acquire Mariana Oncology to strengthen its radioligand therapy pipeline along with expanding research infrastructure & clinical supply capabilities. The transaction will further support Novartis in oncology & RLT platform innovation
- Under the acquisition, Mariana will receive $1B up front plus an additional $750M on achieving pre-specified milestones
- The acquisition also adds diverse RLT portfolio targeting multiple solid tumors like breast, prostate and lung cancer incl. MC-339 (Ac-based RLT) being developed for small cell lung cancer, to Novartis’ pipeline
Ref: Novartis | Image: Novartis
Related News:- PeptiDream Expands its Partnership with Novartis for Peptide Discovery
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
